ENABLE Registry Study in Phoenix: BRIUMVI Research for Relapsing MS

People living with relapsing multiple sclerosis often have practical questions that go beyond a diagnosis: What does treatment look like over time? How are experiences in everyday care collected? And where can adults in Phoenix learn about research opportunities without assuming that a study is the same as a new treatment?

Arizona Neuroscience Research currently lists the ENABLE study (TG1101-RMS406) among its enrolling studies. ENABLE is a Phase 4, observational registry for adults with relapsing multiple sclerosis (RMS) who have been prescribed BRIUMVI® (ublituximab-xiiy) in routine care. The study follows participants over time to collect information about safety, treatment experience, and outcomes in the real world. It does not promise a benefit, and the study team determines whether someone may be eligible.

For people in Phoenix and across the Valley, this distinction matters. A registry can help researchers understand what happens outside a tightly controlled trial, while keeping treatment decisions between a patient and their treating clinician. If you would like to ask whether ENABLE is currently available at Arizona Neuroscience Research, start with the Current Studies page or the Volunteer Today form.

What is the ENABLE registry study?

ENABLE is the study name for TG1101-RMS406, described as a longitudinal, Phase 4 observational registry. Its focus is the real-world experience of adults with relapsing forms of multiple sclerosis who are treated with BRIUMVI. In an observational study, researchers collect information about care that is already taking place; the study is not designed to assign participants to a new treatment group.

That is different from many interventional clinical trials. In an interventional study, a protocol may assign a participant to receive a study intervention, sometimes by randomization. In a registry, the research team records specified information over time. ENABLE is not described by Arizona Neuroscience Research as a placebo-controlled or randomized study. It is also not a guarantee that a person will receive, continue, or change any medication.

Arizona Neuroscience Research lists the study as enrolling and describes it as a 96-week registry. The public ClinicalTrials.gov record is a useful source for the study identification and overall design, but a registry’s overall listing does not by itself confirm a local opening. Availability, screening, and eligibility should always be confirmed directly with the Arizona Neuroscience Research team.

Why real-world MS research is useful

Clinical research answers different kinds of questions. Carefully controlled trials are important for evaluating a treatment under a planned protocol. Observational research adds another view: it can describe experiences in routine clinical practice. Researchers may look at patterns such as treatment use, reported outcomes, safety information, and the practical experience of receiving care over time.

For relapsing MS, the word “relapsing” refers to forms of the condition in which new or returning neurologic symptoms can occur as relapses. People’s experience can vary widely. Some may notice sensory changes, vision symptoms, weakness, balance changes, fatigue, or other concerns. Those symptoms can have many possible causes, so a change in symptoms deserves a conversation with a clinician rather than an assumption about what it means.

A registry cannot prove that one person’s result will match another person’s. It also cannot replace medical care. Its value is in the information gathered across participants over time. That information may help broaden the understanding of treatment use in everyday settings, but it does not predict an individual outcome or establish that a treatment is right for any particular person.

BRIUMVI and the scope of this research

BRIUMVI is the brand name for ublituximab-xiiy. The ENABLE registry concerns adults with RMS who have been prescribed BRIUMVI as part of their clinical care. The research listing is not a recommendation to start, stop, or change any medicine. Medication decisions depend on a person’s diagnosis, medical history, prior care, current health, and discussion with their treating clinician.

It is also important to separate a marketed medicine from a research question. A Phase 4 observational registry is designed to gather additional information after a treatment is in use. It is not the same as a study testing an experimental drug against a placebo. Research participation can still involve screening, consent, collection of health information, scheduled contacts, and study-specific procedures. The exact process for ENABLE should come from the local research staff, who can explain what is required before anyone decides whether to participate.

What “observational” means in plain language

• No treatment promise: Enrollment does not guarantee a health benefit or a particular treatment outcome.
• No assumed medication change: ENABLE is described as observing people who have already been prescribed BRIUMVI in routine care.
• Information over time: The registry follows participants for a planned period and records study-specified information.
• Local screening still matters: A person may be interested and still not meet the study’s current criteria.

If a study is randomized or includes a placebo, consent materials should explain that clearly before enrollment. Arizona Neuroscience Research’s current description of ENABLE identifies it as observational. If you have questions about any study term, ask the research team to explain it in everyday language.

Who may want to ask about ENABLE in Phoenix?

The clearest starting point is an adult with relapsing MS who has been prescribed BRIUMVI and would like to learn whether the ENABLE registry is currently recruiting locally. That is not an eligibility decision. The research team uses the current protocol and screening process to determine who can take part.

It can help to arrive with a few questions prepared. You might ask whether the study is enrolling at the Phoenix location, what records or information may be needed for screening, how long participation may last, what visits or contacts are expected, and whether your usual clinical care continues separately. You can also ask what information the study collects and how the team handles questions that arise during participation.

Arizona Neuroscience Research has Phoenix locations listed on its website, including locations near Bell Road and in the Biltmore area. Local details can change, so use the site’s current contact and volunteer pages for the most accurate information. No one should delay needed medical care while waiting to hear about research eligibility.

What screening and informed consent may involve

Before a person joins a research study, the research team reviews the study and asks questions to see whether the protocol may fit. This is called screening. Screening may include discussing medical history, current diagnosis, treatment information, and other criteria specified by the protocol. Being screened does not mean a person is enrolled.

If the study appears to be a match, the team should provide an informed-consent document. Informed consent is more than a signature. It is a conversation about the purpose of the study, what participation involves, possible risks or inconveniences, privacy, alternatives, and the right to ask questions. A prospective participant should have time to read the materials and discuss questions with people they trust or with their clinician.

Research participation is voluntary. A person can ask about the study without making a commitment. The team can explain whether enrollment is open, what the next step would be, and what is known from the current protocol. If a detail is not confirmed, the right answer is simply to ask the site rather than rely on an older blog post or a general online listing.

Questions to bring to the research team

A thoughtful conversation helps set expectations. Consider asking:

• Is ENABLE (TG1101-RMS406) currently enrolling at Arizona Neuroscience Research?
• Does the study fit someone who is already prescribed BRIUMVI?
• What is the difference between my regular MS care and the registry procedures?
• What visits, phone calls, surveys, or records are involved?
• How long is the follow-up period for a participant?
• What are the known study-specific risks, privacy practices, and alternatives?
• Who should I contact if I have a change in symptoms or a concern during participation?

These questions are not a substitute for medical advice. They are a practical way to understand a research opportunity before deciding whether screening makes sense.

When neurologic symptoms need urgent attention

Research information should never delay emergency care. Call 911 or seek emergency help for sudden symptoms such as new facial drooping, trouble speaking, sudden severe weakness, loss of consciousness, a seizure lasting five minutes or longer, or a sudden severe headache unlike usual symptoms. For new, worsening, or concerning MS-related symptoms that are not an emergency, contact your treating clinician promptly for guidance.

Frequently asked questions about the ENABLE BRIUMVI registry

Is ENABLE a clinical trial?

ENABLE is clinical research, specifically a Phase 4 observational registry. It is not described on Arizona Neuroscience Research’s current study listing as a randomized, placebo-controlled treatment trial.

Is Arizona Neuroscience Research enrolling for ENABLE?

Arizona Neuroscience Research currently lists ENABLE as enrolling. Local availability and screening can change, so contact the team for the current status before making plans.

Will joining ENABLE change my MS treatment?

The registry is described as following adults who have been prescribed BRIUMVI in routine care. Do not change treatment based on a blog post. Ask your treating clinician and the study team how research participation relates to your own care.

Does a registry provide a treatment benefit?

No benefit can be promised. A registry gathers information and may not provide direct benefit to an individual participant. The consent process should explain the potential risks, inconveniences, and any possible benefits that are known for the study.

How do I find out whether I qualify?

Use Arizona Neuroscience Research’s Volunteer Today page or contact the team through its current website. The site staff can explain current screening steps and determine eligibility under the protocol.

Learn more from Arizona Neuroscience Research

Arizona Neuroscience Research is currently listing the ENABLE registry as an option for adults with relapsing MS who have been prescribed BRIUMVI. To review the study in context, visit the Current Studies page and the public ClinicalTrials.gov record for NCT06433752. If you would like to ask about current Phoenix availability or screening, submit a request through Volunteer Today.

Medical and research information in this article is educational and does not replace individualized medical advice, diagnosis, or treatment. Research participation is voluntary, and eligibility, availability, procedures, risks, and benefits must be reviewed with the research team.

How to compare research information with your own care plan

It is reasonable to be curious about a study while also wanting to protect the care plan you already have. A useful first step is to keep the two conversations separate. Your treating clinician can help you discuss symptoms, diagnosis, and treatment decisions. The research team can explain the ENABLE protocol, current local availability, and the details of screening and consent. Both conversations can inform your questions, but neither should be rushed.

Bring an updated medication list and any questions you have about timing, records, travel, or study contacts. Ask what happens if you decide not to participate, and ask whom to call if you have a research question later. A clear answer may be that a detail is still being checked; that is better than assuming an answer. Participation should fit your circumstances only after you understand the current requirements and choose freely.

For Arizona residents looking for relapsing MS research in Phoenix, the best next step is a direct conversation with Arizona Neuroscience Research. The team can confirm whether ENABLE remains open, whether it is appropriate to consider screening, and what the current study materials say.